FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer

Oncotarget

Volumn 2, Issue 1-2, 2011, Pages 69-75

  Scrimieri, Francesca ^a   Calhoun, Eric S ^a,b   Patel, Kalpesh ^a   Gupta, Rigu ^a   Huso, David L ^c   Hruban, Ralph H ^a,c   Kern, Scott E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ALMA COLLEGE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cancer; In frame deletion; Internal rearrangements

Indexed keywords

FAMILY WITH SEQUENCE SILIMARITY 190 MEMBER A PROTEIN; REGULATOR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIGEN; MESSENGER RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; EXON; FAMILY WITH SEQUENCE SILIMARITY 190 MEMBER A GENE; GENE DELETION; GENE LOCATION; GENE REARRANGEMENT; GENE STRUCTURE; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MOUSE; MUTATOR GENE; NEWBORN; NONHUMAN; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; 5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ANIMAL; GENE ORDER; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; BASE SEQUENCE; CELL LINE, TUMOR; GENE ORDER; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79960864358     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.220     Document Type: Article

References (26)

1. Glover TW. Common fragile sites. Cancer Lett. 2006; 232: 4-12.
2. Kannan K, Munirajan AK, Bhuvarahamurthy V, Mohanprasad BK, Shankar P, Tsuchida N, Shanmugam G. FHIT gene mutations and single nucleotide polymorphism in Indian oral and cervical squamous cell carcinomas. Oral Oncol. 2000; 36: 189-193.
3. Kannan K, Krishnamurthy J, Feng J, Nakajima T, Tsuchida N, Shanmugam G. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Int J Oncol. 2000; 17: 1031-1035.
4. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA, Huebner K. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 2006; 232: 27-36.
5. Richards RI. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 2001; 17: 339-345.
6. Rozier L, El-Achkar E, Apiou F, Debatisse M. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene. 2004; 23: 6872-6880.
7. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, Widaa S, Hinton J, Fahey C, Fu B, Swamy S, Dalgliesh GL, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010; 463: 893-898.
8. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, Clouston AD, Hayward NK, Whiteman DC. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density singlenucleotide polymorphism arrays. Cancer Res. 2008; 68: 4163-4172.
9. Calhoun ES, Hucl T, Gallmeier E, West KM, Arking DE, Maitra A, Iacobuzio-Donahue CA, Chakravarti A, Hruban RH, Kern SE. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 2006; 66: 7920-7928.
10. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback R, Ligon AH, Cho YJ, Haery L, Greulich H, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463: 899-905.
11. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992; 89: 2965-2969.
12. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Janne PA, Girard L, Minna J, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005; 65: 5561-5570.
13. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467:1109-13.
14. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene. 2002; 21: 1832-1840.
15. Sozzi G, Huebner K, Croce CM. FHIT in human cancer. Adv Cancer Res. 1998; 74: 141-166.
16. Wang L, Darling J, Zhang JS, Qian CP, Hartmann L, Conover C, Jenkins R, Smith DI. Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. Oncogene. 1998; 16: 635-642.
17. Hilgers W, Kern SE. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer. 1999; 26: 1-12.
18. Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI. An FHIT tumor suppressor gene? Genes Chromosomes Cancer. 1998; 21: 281-289.
19. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324: 217.
20. Uckun FM, Goodman P, Ma H, Dibirdik I, Qaz Si. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia. Proc Natl Acad Sci U S A. 2010; 107: 16852-16857.
21. Lee MP, Feinberg AP. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res. 1997; 57: 3131-3134.
22. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu VE. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010; 2: 20ra14.
23. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994; 8: 27-32.
24. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, Troup WJ, Romm JM, Doheny K, Pugh E, Yeo CJ, Goggins MG, Hruban RH, Kern SE. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res. 2004; 64: 871-875.
25. Brody JR, Calhoun ES, Gallmeier E, Creavalle TD, Kern SE. Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media. Biotechniques. 2004; 37: 598, 600, 602.
26. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995; 41: 178-228.